ObjectiveTo explore the efficacy and safety of milnacipran in the treatment of elderly patients with first-episode generalized anxiety disorder. MethodsA total of 72 elderly patients with first-episode generalized anxiety disorder who were hospitalized in our hospital from May 2019 to May 2020 were enrolled and divided into study group and control group by the random number method, with 36 cases in each group. Patients in the observation group were treated with milnacipran, and patients in the control group were treated with escitalopram, for a 6-week treatment course. The Hamilton Anxiety Scale (HAMA) and Clinical Global Impression Scale (CGI-SI) scores before and after treatment were compared between the two groups. The clinical efficacy, Asberg Side Effects Rating Scale (SERS) for antidepressant score and the occurrence of adverse reactions were compared between the two groups. ResultsBefore treatment, there were no statistically significant differences in the scores of HAMA and CGI-SI between the two groups (P＞0.05). After 6 weeks of treatment, the HAMA and CGI-SI scores significantly decreased in both groups; compared with the control group, the study group yielded lower scores of HAMA and CGI-SI, with statistically significant differences (P＜0.05). The clinical curative effect in the study group was superior to that in the control group, with a statistically significant difference (P＜0.05). There were no statistically significant differences in the SERS score before and after treatment, and the incidence of adverse drug reactions between the two groups. ConclusionMilnacipran has superior efficacy to escitalopram in the treatment of elderly patients with first-episode generalized anxiety disorder, and the adverse reactions of both drugs are mild and tolerated by patients.

无